NRCS
NOTICE OF REGISTRATION CONFIRMATION EMAILED
04/22/2025
Back to search
Official data from USPTO
RADIOHYBRID
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
RADIOHYBRID
ST13
US500000097695250Class
1, 5, 42, 44
Filing
97695250
Registration
7772317
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
24
Latest update
04/23/2025
Trademark type
Word
Nice classes
1, 5, 42, 44
Filing date
11/29/2022
Registration date
04/22/2025
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
04/22/2025
Last transaction
04/23/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Supplemental Register
Filing basis
Intent to use, Foreign priority
Drawing code
4
Owner type
03
Owner location
Munich, DE
Examiner
GLUECK, CHRISTOPHER
Current location
FILE REPOSITORY (FRANCONIA)
Holders and representatives
Holders
T. M. (pessoa física)
Representatives
Andrew D. Bochner BOCHNER PLLC
Technical classification
Nice Classes
Class 1Class 5Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Chemicals for use in scientific researchother than for medical or veterinary purposes; diagnostic chemicals for scientific use; Positron Emission Tomography (PET) imaging tracer chemicals for scientific and laboratory use; radioactive elements for scientific purposes; diagnostic scanning agents for in-vivo use other than medical purposes; chemicals for use in molecular imaging for scientific or research use
Class 5
Medicalpharmaceutical and veterinary preparations for diagnosismonitoring and treatment of cancer; sanitary preparations for medical use; diagnostic preparations for medical purposes; medical preparations in the nature of biometallic compounds for consumption or injection for use in medical imaging; contrast agents for use in medical imaging; amino acids for medical purposes; radioactive substances for medical purposes; reagents for medical use; Positron Emission Tomography (PET) tracer chemicals for medical use; Positron Emission Tomography (PET) tracer chemicals prepared for ingestion or injection into humans and animals for medical purposes; diagnostic chemicals for medical purposes; Therapeutic pharmaceutical for the treatment of cancer; reagents for medical purposes; diagnostic scanning agents for medical use; pharmaceutical preparationsradiotherapeutic preparations and radio diagnostic preparations; Diagnostic medical preparations for use in molecular imaging; pharmaceutical preparationsradiotherapeutic preparations and radiodiagnostic preparations; pharmaceutical preparations for the treatment of cancer; diagnostic radiopharmaceutical preparations; radiopharmaceutical productsradiopharmaceutical imaging and detection agents for diagnosing and monitoring cancer; Radiopharmaceuticals used in the field of nuclear medicineintended for medical imaging and therapy; Pharmaceutical preparationsalpha- and beta-emitting radionuclides for use in radionuclide therapy; synthetic amino acids for medical purposesuse in Positron Emission Tomography (PET) imaging and radionuclide therapy; reagents for medical useuse in Positron Emission Tomography (PET) imaging and radionuclide therapy
Class 42
Scientific and technological servicesresearch and design in the field of industrial analysis; industrial analysis and research services in the field of radiopharmaceuticals; design and development of computer hardware and software; product design and development in the field of Positron Emission Tomography (PET) imaging and radionuclide therapy; medical and scientific research in the field of disease diagnosis and treatment; scientific and medical research in the field of molecular imaging; development of molecular imaging products; development of radionuclide therapy products; diagnostic imaging for scientific purposes; scientific imaging services; medical laboratory services; medical and pharmacological research services; scientific research consulting in the field of medical imaging; Medical laboratory services
Class 44
Medical clinic services; Positron Emission Tomography (PET) imaging services; medical imaging services; medical analysis for the diagnosis and treatment of persons; medical consultations
Publications
History of USPTO decisions and trademark events.
24 publications found
R.SR
REGISTERED-SUPPLEMENTAL REGISTER
04/22/2025
ERRR
ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
01/30/2025
CNTA
APPROVED FOR REGISTRATION SUPPLEMENTAL REGISTER
01/27/2025
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
01/24/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
01/24/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/24/2025
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
01/23/2025
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
11/01/2024
GNFR
FINAL REFUSAL E-MAILED
11/01/2024
CNFR
FINAL REFUSAL WRITTEN
11/01/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
05/06/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
05/06/2024
ALIE
ASSIGNED TO LIE
05/06/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
12/14/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
09/14/2023
GNRT
NON-FINAL ACTION E-MAILED
09/14/2023
CNRT
NON-FINAL ACTION WRITTEN
09/14/2023
DOCK
ASSIGNED TO EXAMINER
09/08/2023
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
07/24/2023
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
07/24/2023
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
07/24/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
12/21/2022
NWAP
NEW APPLICATION ENTERED
12/02/2022
Continuous trademark protection
Get notified about every new filing that threatens RADIOHYBRID or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.